文献速递神经肿瘤

单次与分次伽玛刀放射外科治疗邻近视路的无功能垂体腺瘤:一项多中心倾向性评分匹配研究

Single Versus Fractionated Gamma Knife Radiosurgery for Nonfunctioning Pituitary Adenomas Close to the Optic Pathway: A Multicenter Propensity Score Matched Study.
PubMed 文献 · Neurosurgery · 2024-02-20

这项多中心倾向性评分匹配研究回顾性比较了欧洲3天分次伽玛刀(F-GKRS)与美国单次伽玛刀(S-GKRS)治疗邻近视路的残留或复发无功能垂体腺瘤。匹配后各42例,两组在年龄、性别、既往手术次数、肿瘤体积和随访上无差异,7年肿瘤控制与视力恶化风险相当。作者指出未来需更大样本、更长随访的前瞻性研究确认。

要点

  • 匹配后F-GKRS与S-GKRS各42例,末次随访肿瘤控制率分别为95.2%与92.9%(P=0.64)。
  • F-GKRS组1、3、5、7年无进展生存率为100%、97.1%、97.1%、91%。
  • S-GKRS组1、3、5、7年无进展生存率为100%、100%、92.5%、92.5%。

核心结论

  • 在邻近视路的无功能垂体腺瘤治疗中,F-GKRS与S-GKRS在7年时结局与风险相当。
  • 作者指出未来需更大样本、更长随访的前瞻性研究确认该结果。

研究设计与样本

  • 多中心倾向性评分匹配(1:1)回顾性研究,比较欧洲3天疗程F-GKRS与美国S-GKRS治疗邻近视路的残留或复发无功能垂体腺瘤。
  • 共纳入84例患者,S-GKRS组42例,F-GKRS组42例。

主要发现

  • 两组在年龄、性别、既往手术次数、肿瘤体积和随访上无差异。
  • F-GKRS组与S-GKRS组平均随访分别为60.2±37.0个月与62.4±37.4个月(P=0.38)。
  • 末次随访总肿瘤控制率F-GKRS组为95.2%,S-GKRS组为92.9%(P=0.64)。
  • F-GKRS组1年、3年、5年、7年无进展生存率分别为100%、97.1%、97.1%、91%。
  • S-GKRS组1年、3年、5年、7年无进展生存率分别为100%、100%、92.5%、92.5%。

局限性

  • 原文结论指出未来需更大样本、更长随访的前瞻性研究确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Gamma Knife radiosurgery (GKRS), typically administered in a single session (S-GKRS), is an effective treatment for nonfunctioning pituitary adenoma (NFPA). For lesions close to the optic pathway, the use of hypofractionated radiosurgery is growing. This study seeks to compare the results of S-GKRS vs fractionated-GKRS (F-GKRS) for NFPAs adjacent to the optic pathway. METHODS: Two cohorts of patients with residual or recurrent NFPAs in contact to the optic pathway were retrospectively included in this study: (1) a group of patients who underwent a 3-day course of F-GKRS in Europe and (2) a group of patients treated with S-GKRS in the United States. A propensity score matching (ratio 1:1) was carried out to obtain and compare 2 homogeneous groups of patients with NFPA. RESULTS: A total of 84 patients were included for analysis (42 in the S-GKRS cohort and 42 in the F-GKRS group). The 2 cohorts did not differ for age, sex, number of previous surgical procedure, tumor volume, and follow-up. The mean follow-up was 60.2 ± 37.0 months and 62.4 ± 37.4 months for F-GKRS and S-GKRS cohort, respectively ( P = .38). The overall tumor control at last follow-up was achieved in 95.2% and 92.9% of patients in F-GKRS and S-GKRS, respectively ( P = .64). The 1-year, 3-year, 5-year, and 7-year progression-free survival rate after F-GKRS was 100%, 97.1%, 97.1%, and 91%, respectively. In the S-GKRS sample, progression-free survival rates were 100%, 100%, 92.5%, and 92.5% at 1, 3, 5, and 7 years after treatment, respectively. Two patients (4.7%) from the F-GKRS cohort and 2 (4.7%) from the S-GKRS cohort sustained visual worsening after radiosurgery ( P = 1.0). CONCLUSION: In the management of NFPAs adjacent to the optic pathway both F-GKRS and S-GKRS had comparable outcomes and risks at 7 years. Future prospective studies including larger cohorts with longer follow-up are needed to confirm our results.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Albano L, Losa M, Barzaghi LR, et al. Single Versus Fractionated Gamma Knife Radiosurgery for Nonfunctioning Pituitary Adenomas Close to the Optic Pathway: A Multicenter Propensity Score Matched Study. Neurosurgery. 2024. PMID: 38376150. doi:10.1227/neu.0000000000002886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。